Temozolomide (TEM) vs Temozolomide-Capecitabine (CAP) in Advanced Pancreatic NET (pNET): A Multicenter Retrospective Analysis of 138 Patients Using a Propensity Score - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2019

Temozolomide (TEM) vs Temozolomide-Capecitabine (CAP) in Advanced Pancreatic NET (pNET): A Multicenter Retrospective Analysis of 138 Patients Using a Propensity Score

Fichier non déposé

Dates et versions

hal-04495620 , version 1 (08-03-2024)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

  • HAL Id : hal-04495620 , version 1

Citer

Thomas Walter. Temozolomide (TEM) vs Temozolomide-Capecitabine (CAP) in Advanced Pancreatic NET (pNET): A Multicenter Retrospective Analysis of 138 Patients Using a Propensity Score. 6th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Mar 2019, Barcelona (ES), Spain. pp.(H08). ⟨hal-04495620⟩
4 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More